Paclitaxel
For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.
Active substance: Paclitaxel
Examples of brand names: Taxol [DE]
ATC code: L01CD01
Main use (for orientation): Selected cancers
Documented research summary
Several preclinical neuroprotection/antitumour studies and small clinical supportive CBD studies. Results depend on model, sequence and formulation, including antagonism; no general clinical pharmacokinetic safety or tumour efficacy proven.
Uncertainties and limitations
Intravenous albumin-bound particles; clearance/distribution differ from solvent-containing paclitaxel. Do not equate label pharmacokinetics between formulations.
Shared enzymes must not be equated with clinical evidence of an interaction; CBD/THC findings cannot be extrapolated to other cannabinoids.
PMID38396679 (CBG/PDAC) and 32992648 (CBD/ozone/PDAC): abstracts mention combinations but no clearly separated paclitaxel pair result; full-text assessment unresolved. PMID36839877 has author correction 37765336. Preprint PPR1251685 not peer reviewed.
Separately recorded findings
14 separately recorded findings. Each statement applies to its documented study context.
CBD – clinical signals
Finding ID: B0203
Type of result: Clinical signals
Observation: With carboplatin/paclitaxel, CBD improved early objective high-frequency vibrometry but not patient-reported neuropathy items significantly.
Mechanism: Neuropathy symptoms
Study type: Small non-randomised supportive human study
Context studied: 300 mg/day for 8 days, 54 participants overall receiving CAPOX or carboplatin/paclitaxel; not randomised, age differences.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: Mixed chemotherapies, no paclitaxel pharmacokinetic endpoint; short-term and insufficient for safety/antitumour efficacy.
Original sources for this finding: Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy. [BMED35933415]
CBD – clinical signals
Finding ID: B0204
Type of result: Clinical signals
Observation: Pilot report showed better discrimination of certain taste intensities, without a lean-body-mass effect.
Mechanism: Taste perception
Study type: Small non-randomised supportive human study
Context studied: 22 intervention/10 control; paclitaxel or oxaliplatin regimens; 300 mg/day for 8 days.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: Regimens not separated; probably overlapping pilot context with the neuropathy study, not independent pharmacokinetic evidence.
Original sources for this finding: Prevention of Taste Alterations in Patients with Cancer Receiving Paclitaxel- or Oxaliplatin-Based Chemotherapy-A Pilot Trial of Cannabidiol. [BMED37447339]
CBD – laboratory and animal studies
Finding ID: B0205
Type of result: Preclinical evidence
Observation: CBD prevented or reduced paclitaxel-induced allodynia in several rodent models.
Mechanism: Neuropathy prevention
Study type: Cell/animal model
Context studied: 5-HT1A/TLR4/mitochondrial mechanisms depend on model; no paclitaxel concentration measurement.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice. [BMED21737705]; Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy. [BMED24117398]; Cannabidiol prevents chemotherapy-induced neuropathic pain by modulating spinal TLR4 via endocannabinoid system activation. [BMED36946366]; Prevention of Allodynia and Hyperalgesia by Cannabidiol in a Rat Model of Chemotherapy-Induced Peripheral Neuropathy. [BMED40622941]; Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity. [BMED31077084]
CBD – laboratory and animal studies
Finding ID: B0206
Type of result: Preclinical evidence
Observation: CBD prevented neuropathy but did not reverse established mechanical sensitivity in the KLS-13019 comparison; GPR55 culture response weaker than the analogue.
Mechanism: Prevention versus reversal of established neuropathy
Study type: Cell/animal model
Context studied: Model-dependent limitation, not a general analgesic effect.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS-13019 in mouse models of pain and reinforcement. [BMED33822373]; Knockdown siRNA Targeting GPR55 Reveals Significant Differences Between the Anti-inflammatory Actions of KLS-13019 and Cannabidiol. [BMED38602576]
CBD – laboratory and animal studies
Finding ID: B0207
Type of result: Preclinical evidence
Observation: NAPE-PLD knockout abolished CBD antiallodynia.
Mechanism: NAPE-PLD/PPAR signalling pathway
Study type: Cell/animal model
Context studied: 2026 preprint; mouse model.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: Not peer reviewed; mechanistic hypothesis, not clinically validated.
Original sources for this finding: Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) [BMEDPPR1251685]
CBG – laboratory and animal studies
Finding ID: B0208
Type of result: Preclinical evidence
Observation: Prophylactic CBG protected male and female mice from mechanical sensitivity; PAG neuroinflammation reduced particularly in females.
Mechanism: Neuroinflammation/pain behaviour
Study type: Cell/animal model
Context studied: CBG 10 mg/kg intraperitoneally before paclitaxel; not a clinical dose.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Paclitaxel-Associated Mechanical Sensitivity and Neuroinflammation Are Sex-, Time-, and Site-Specific and Prevented through Cannabigerol Administration in C57Bl/6 Mice. [BMED38673862]
CBD/THCV combination – laboratory and animal studies
Finding ID: B0209
Type of result: Preclinical evidence
Observation: Combination was stronger than individual treatments against thermal/mechanical symptoms in mice; 5-HT1A/CB1 involvement.
Mechanism: Neuroprotection
Study type: Cell/animal model
Context studied: Six groups of 6 mice plus dorsal-root-ganglion cultures; not human THCV evidence.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents. [BMED35303507]
THC/CBD (individually and combined) – laboratory and animal studies
Finding ID: B0210
Type of result: Preclinical evidence
Observation: Both individual substances reduced paclitaxel allodynia; very low individually ineffective doses acted synergistically in combination.
Mechanism: Neuropathy symptoms
Study type: Cell/animal model
Context studied: Mouse; not a clinical paclitaxel-clearance effect.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. [BMED28548225]
THC/CBD formulations – laboratory and animal studies
Finding ID: B0211
Type of result: Preclinical evidence
Observation: 1:1 prevented cold allodynia, 1:20 thermal/mechanical hypersensitivity; other paclitaxel effects not reversed.
Mechanism: Pain behaviour
Study type: Cell/animal model
Context studied: Oral administration in male rats; no additional toxicity in this limited experiment.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Early oral administration of THC:CBD formulations prevent pain-related behaviors without exacerbating paclitaxel-induced changes in weight, locomotion, and anxiety in a rat model of chemotherapy-induced neuropathy. [BMED40163146]
THC-dominant cannabis/cannabis extract – laboratory and animal studies
Finding ID: B0212
Type of result: Preclinical evidence
Observation: Cannabis preparations showed reduced nociception or better neurite preservation in separate preclinical models.
Mechanism: Neuroprotection/analgesia
Study type: Cell/animal model
Context studied: Vaporised cannabis containing 10.3% THC/0.05% CBD, JG hemp extract and Cannabixir cell experiments are different products, not isolated THC.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: A Functional Imaging Study in Rats. [BMED33622657]; The Potential Antinociceptive Effect and Mechanism of Cannabis sativa L. Extract on Paclitaxel-Induced Neuropathic Pain in Rats Uncovered by Multi-Omics Analysis. [BMED38731449]; The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth. [BMED38933665]
CBD – laboratory and animal studies
Finding ID: B0213
Type of result: Preclinical evidence
Observation: Additive/synergistic antiproliferative effects in selected breast, lung, ovarian and glioblastoma models.
Mechanism: Antitumour combination
Study type: Cell/animal model
Context studied: Cell models, partly xenograft/in ovo; different dose sequences and formulations.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Cannabidiol induces apoptosis and autophagy via STAT3 and NF-κB inhibition and synergistically enhances paclitaxel efficacy in non-small cell lung cancer. [BMED42364563]; Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms. [BMED34576262]; CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer. [BMED31811927]; Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles. [BMED32682943]; From Screening to a Nanotechnological Platform: Cannabidiol-Chemotherapy Co-Loaded Lipid Nanocapsules for Glioblastoma Multiforme Treatment. [BMED41471054]
CBD – laboratory and animal studies
Finding ID: B0214
Type of result: Preclinical evidence
Observation: Simultaneous CBD/paclitaxel administration was antagonistic in SK-OV-3; pretreatment changed the effect.
Mechanism: Combination antagonism
Study type: Cell/animal model
Context studied: Chou–Talalay cell model; important contrasting observation to blanket synergy.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Combination of Cannabidiol with Cisplatin or Paclitaxel Analysis Using the Chou-Talalay Method and Chemo-Sensitization Evaluation in Platinum-Resistant Ovarian Cancer Cells. [BMED40002932]
CBD in nanocarriers – laboratory and animal studies
Finding ID: B0215
Type of result: Preclinical evidence
Observation: Co-loaded nanoparticles or CBD milk exosomes enhanced paclitaxel cytotoxicity/model tumour effects.
Mechanism: Formulation-dependent combination
Study type: Cell/animal model
Context studied: Melanoma cells or doxorubicin-resistant breast-cancer xenografts; carrier altered CBD bioavailability.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Codelivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity against Melanoma Cells. [BMED40488002]; In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts. [BMED40936044]
CBD in extracellular vesicles – laboratory and animal studies
Finding ID: B0216
Type of result: Preclinical evidence
Observation: CBD extracellular vesicles reduced paclitaxel hypersensitivity more than CBD or vesicles alone.
Mechanism: Neuroprotection
Study type: Cell/animal model
Context studied: Mouse; AMPK/mitochondria; author correction considered.
Clinical interpretation: Study-specific, not a recommendation for use
Limitations and uncertainties: No clinical pharmacokinetic/tumour-efficacy confirmation; abstract-based.
Original sources for this finding: Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy. [BMED36839877]; Correction: Kalvala et al. Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy. Pharmaceutics 2023, 15, 554. [BMED37765336]
References and access status
[V2_LABEL_D0405] PACLITAXEL 100MG PER VIAL (PACLITAXEL PROTEIN-BOUND PARTICLES) INJECTION, POWDER, LYOPHILIZED, FOR SUSPENSION [EXELAN PHARMACEUTICALS INC.]
Original source / bibliographic reference
Authors: EXELAN PHARMACEUTICALS INC.
Year: 2026
Source type: Official US SPL / DailyMed
Source access – 23 October 2026: Source destination was accessible when checked.
Bibliographic attribution or source identity cross-checked.
[BMED42364563] Cannabidiol induces apoptosis and autophagy via STAT3 and NF-κB inhibition and synergistically enhances paclitaxel efficacy in non-small cell lung cancer.
Original source / bibliographic reference
Authors: Kim NY, Jung YY, Yang MH, Um JY, Sethi G, Ahn KS.
Year: 2026
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.phymed.2026.158490
PMID: 42364563
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED40002932] Combination of Cannabidiol with Cisplatin or Paclitaxel Analysis Using the Chou-Talalay Method and Chemo-Sensitization Evaluation in Platinum-Resistant Ovarian Cancer Cells.
Original source / bibliographic reference
Authors: Ismail J, Shebaby W, Azar Atallah S, Taleb RI, Kawrani S, Faour W, Mroueh M.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.3390/biomedicines13020520
PMID: 40002932
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED41471054] From Screening to a Nanotechnological Platform: Cannabidiol-Chemotherapy Co-Loaded Lipid Nanocapsules for Glioblastoma Multiforme Treatment.
Original source / bibliographic reference
Authors: Gómez-Lázaro L, Aparicio-Blanco J, Fraguas-Sánchez AI, Montejo-Rubio MC, Martín-Sabroso C, Torres-Suárez AI.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.3390/pharmaceutics17121537
PMID: 41471054
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED40488002] Codelivery of Paclitaxel and Cannabidiol in Lipid Nanoparticles Enhances Cytotoxicity against Melanoma Cells.
Original source / bibliographic reference
Authors: de Carvalho FV, Geronimo G, de Moura LD, Mendonça TC, Breitkreitz MC, de Paula E, Rodrigues da Silva GH.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.1021/acsomega.5c00689
PMID: 40488002
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED38673862] Paclitaxel-Associated Mechanical Sensitivity and Neuroinflammation Are Sex-, Time-, and Site-Specific and Prevented through Cannabigerol Administration in C57Bl/6 Mice.
Original source / bibliographic reference
Authors: Li H, Ward SJ.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.3390/ijms25084277
PMID: 38673862
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED38396679] Cannabigerol Induces Autophagic Cell Death by Inhibiting EGFR-RAS Pathways in Human Pancreatic Ductal Adenocarcinoma Cell Lines.
Original source / bibliographic reference
Authors: Zeppa L, Aguzzi C, Morelli MB, Marinelli O, Giangrossi M, Luongo M, Amantini C, Santoni G, Nabissi M.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.3390/ijms25042001
PMID: 38396679
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED36839877] Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy.
Original source / bibliographic reference
Authors: Kalvala AK, Bagde A, Arthur P, Kulkarni T, Bhattacharya S, Surapaneni S, Patel NK, Nimma R, Gebeyehu A, Kommineni N, Meckes DG, Sun L, Banjara B, Mosley-Kellum K, Dinh TC, Singh M.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.3390/pharmaceutics15020554
PMID: 36839877
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED37447339] Prevention of Taste Alterations in Patients with Cancer Receiving Paclitaxel- or Oxaliplatin-Based Chemotherapy-A Pilot Trial of Cannabidiol.
Original source / bibliographic reference
Authors: Dominiak HSH, Hasselsteen SD, Nielsen SW, Andersen JR, Herrstedt J.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.3390/nu15133014
PMID: 37447339
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED35933415] Oral cannabidiol for prevention of acute and transient chemotherapy-induced peripheral neuropathy.
Original source / bibliographic reference
Authors: Nielsen SW, Hasselsteen SD, Dominiak HSH, Labudovic D, Reiter L, Dalton SO, Herrstedt J.
Year: 2022
Source type: Publication; title and abstract reviewed
DOI: 10.1007/s00520-022-07312-y
PMID: 35933415
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED35303507] Role of Cannabidiol and Tetrahydrocannabivarin on Paclitaxel-induced neuropathic pain in rodents.
Original source / bibliographic reference
Authors: Kumar Kalvala A, Bagde A, Arthur P, Kumar Surapaneni S, Ramesh N, Nathani A, Singh M.
Year: 2022
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.intimp.2022.108693
PMID: 35303507
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED40163146] Early oral administration of THC:CBD formulations prevent pain-related behaviors without exacerbating paclitaxel-induced changes in weight, locomotion, and anxiety in a rat model of chemotherapy-induced neuropathy.
Original source / bibliographic reference
Authors: Soriano D, Brumovsky PR, Villar MJ, Coronel MF.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.1007/s00213-025-06778-y
PMID: 40163146
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED40622941] Prevention of Allodynia and Hyperalgesia by Cannabidiol in a Rat Model of Chemotherapy-Induced Peripheral Neuropathy.
Original source / bibliographic reference
Authors: Ippolito M, Maddox C, Inam A, Wimmer ME, Ward SJ.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.3791/68079
PMID: 40622941
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED38933665] The potential neuroprotective effects of cannabinoids against paclitaxel-induced peripheral neuropathy: in vitro study on neurite outgrowth.
Original source / bibliographic reference
Authors: Creanga-Murariu I, Filipiuc LE, Gogu MR, Ciorpac M, Cumpat CM, Tamba BI, Alexa-Stratulat T.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.3389/fphar.2024.1395951
PMID: 38933665
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED36946366] Cannabidiol prevents chemotherapy-induced neuropathic pain by modulating spinal TLR4 via endocannabinoid system activation.
Original source / bibliographic reference
Authors: Dos Santos R, Veras F, Netto G, Elisei L, Sorgi C, Faccioli L, Galdino G.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.1093/jpp/rgad023
PMID: 36946366
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED28548225] Single and combined effects of Δ9-tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain.
Original source / bibliographic reference
Authors: King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, Ward SJ.
Year: 2017
Source type: Publication; title and abstract reviewed
DOI: 10.1111/bph.13887
PMID: 28548225
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED40936044] In Vivo Pharmacodynamic and Pharmacokinetic Assessment of Cannabidiol-loaded Camel Milk Exosomes in Doxorubicin-resistant Triple-negative Breast Cancer Xenografts.
Original source / bibliographic reference
Authors: Aare M, Padakanti SC, Singh M.
Year: 2025
Source type: Publication; title and abstract reviewed
DOI: 10.1208/s12249-025-03201-9
PMID: 40936044
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED38731449] The Potential Antinociceptive Effect and Mechanism of Cannabis sativa L. Extract on Paclitaxel-Induced Neuropathic Pain in Rats Uncovered by Multi-Omics Analysis.
Original source / bibliographic reference
Authors: Xu Y, Yao L, Guo Y, Shi C, Zhou J, Hua M.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.3390/molecules29091958
PMID: 38731449
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED38602576] Knockdown siRNA Targeting GPR55 Reveals Significant Differences Between the Anti-inflammatory Actions of KLS-13019 and Cannabidiol.
Original source / bibliographic reference
Authors: Brenneman DE, Kinney WA, McDonnell ME, Ippolito MJ, Ward SJ.
Year: 2024
Source type: Publication; title and abstract reviewed
DOI: 10.1007/s12031-024-02217-3
PMID: 38602576
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED37243887] Cannabidiol and mitragynine exhibit differential interactive effects in the attenuation of paclitaxel-induced mechanical allodynia, acute antinociception, and schedule-controlled responding in mice.
Original source / bibliographic reference
Authors: Ortiz YT, Bilbrey JA, Felix JS, Kienegger EA, Mottinelli M, Mukhopadhyay S, McCurdy CR, McMahon LR, Wilkerson JL.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.1007/s43440-023-00498-w
PMID: 37243887
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED33822373] Behavioural and pharmacological effects of cannabidiol (CBD) and the cannabidiol analogue KLS-13019 in mouse models of pain and reinforcement.
Original source / bibliographic reference
Authors: Foss JD, Farkas DJ, Huynh LM, Kinney WA, Brenneman DE, Ward SJ.
Year: 2021
Source type: Publication; title and abstract reviewed
DOI: 10.1111/bph.15486
PMID: 33822373
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED31811927] CBD loaded microparticles as a potential formulation to improve paclitaxel and doxorubicin-based chemotherapy in breast cancer.
Original source / bibliographic reference
Authors: Fraguas-Sánchez AI, Fernández-Carballido A, Simancas-Herbada R, Martin-Sabroso C, Torres-Suárez AI.
Year: 2020
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.ijpharm.2019.118916
PMID: 31811927
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED32682943] Enhancing ovarian cancer conventional chemotherapy through the combination with cannabidiol loaded microparticles.
Original source / bibliographic reference
Authors: Fraguas-Sánchez AI, Fernández-Carballido A, Delie F, Cohen M, Martin-Sabroso C, Mezzanzanica D, Figini M, Satta A, Torres-Suárez AI.
Year: 2020
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.ejpb.2020.07.008
PMID: 32682943
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
DOI – publisher access (access restrictions may apply)
[BMED31077084] Knockdown siRNA Targeting the Mitochondrial Sodium-Calcium Exchanger-1 Inhibits the Protective Effects of Two Cannabinoids Against Acute Paclitaxel Toxicity.
Original source / bibliographic reference
Authors: Brenneman DE, Kinney WA, Ward SJ.
Year: 2019
Source type: Publication; title and abstract reviewed
DOI: 10.1007/s12031-019-01321-z
PMID: 31077084
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED32992648] Cannabidiol and Oxygen-Ozone Combination Induce Cytotoxicity in Human Pancreatic Ductal Adenocarcinoma Cell Lines.
Original source / bibliographic reference
Authors: Luongo M, Marinelli O, Zeppa L, Aguzzi C, Morelli MB, Amantini C, Frassineti A, di Costanzo M, Fanelli A, Santoni G, Nabissi M.
Year: 2020
Source type: Publication; title and abstract reviewed
DOI: 10.3390/cancers12102774
PMID: 32992648
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED33622657] Inhaled Cannabis Suppresses Chemotherapy-Induced Neuropathic Nociception by Decoupling the Raphe Nucleus: A Functional Imaging Study in Rats.
Original source / bibliographic reference
Authors: Alkislar I, Miller AR, Hohmann AG, Sadaka AH, Cai X, Kulkarni P, Ferris CF.
Year: 2021
Source type: Publication; title and abstract reviewed
DOI: 10.1016/j.bpsc.2020.11.015
PMID: 33622657
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED24117398] Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT(1A) receptors without diminishing nervous system function or chemotherapy efficacy.
Original source / bibliographic reference
Authors: Ward SJ, McAllister SD, Kawamura R, Murase R, Neelakantan H, Walker EA.
Year: 2014
Source type: Publication; title and abstract reviewed
DOI: 10.1111/bph.12439
PMID: 24117398
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED21737705] Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice.
Original source / bibliographic reference
Authors: Ward SJ, Ramirez MD, Neelakantan H, Walker EA.
Year: 2011
Source type: Publication; title and abstract reviewed
DOI: 10.1213/ane.0b013e3182283486
PMID: 21737705
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMEDPPR1251685] Cannabidiol attenuates chemotherapy-induced peripheral neuropathic pain through a mechanism that requires the enzyme N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD)
Original source / bibliographic reference
Authors: Jesus CHA, Li A, Luquet S, Mackie K, Hohmann AG.
Year: 2026
Source type: Non-peer-reviewed preprint; abstract read
DOI: 10.64898/2026.06.08.730909
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
DOI – publisher access (access restrictions may apply)
[BMED37765336] Correction: Kalvala et al. Cannabidiol-Loaded Extracellular Vesicles from Human Umbilical Cord Mesenchymal Stem Cells Alleviate Paclitaxel-Induced Peripheral Neuropathy. Pharmaceutics 2023, 15, 554.
Original source / bibliographic reference
Authors: Kalvala AK, Bagde A, Arthur P, Kulkarni T, Bhattacharya S, Surapaneni S, Patel NK, Nimma R, Gebeyehu A, Kommineni N, Li Y, Meckes DG, Sun L, Banjara B, Mosley-Kellum K, Dinh TC, Singh M.
Year: 2023
Source type: Publication; title and abstract reviewed
DOI: 10.3390/pharmaceutics15092200
PMID: 37765336
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
[BMED34576262] Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms.
Original source / bibliographic reference
Authors: Alsherbiny MA, Bhuyan DJ, Low MN, Chang D, Li CG.
Year: 2021
Source type: Publication; title and abstract reviewed
DOI: 10.3390/ijms221810103
PMID: 34576262
Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.
Bibliographic attribution or source identity cross-checked.
PubMed – bibliographic reference / abstract
PubMed Central – archived text
DOI – publisher access (access restrictions may apply)
Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.
Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility
Paclitaxel and cannabinoids: documented findings, evidence, sources and data gaps. Research information for discussion with your doctor or pharmacist.